
© Emil Berl/Bloomberg Business WeekEvans.
Ronald Evans realized the word was out when scores of strangers, some fit and some fat, started showing up at his biology lectures around the country. Soon, via email and voicemail, they were hounding him at all hours. Was it true, some wanted to know, that he had pills that could vaporize fat? Could the pills really, others asked, increase athletic endurance by 70 percent? Would he be interested in coming over and doping a racehorse?
During a lecture for a crowd of 200 in Montreal, a pair of college athletes took the mic and peppered Evans with questions about the pills' potential impact on the effectiveness of human growth hormone and erythropoietin. They ignored his interjections that those two performance-enhancing drugs were banned by most athletic rule-making bodies.
That was 2007. Evans was finishing up a study showing that mice taking the drug, an experimental
GlaxoSmithKline Plc compound called GW501516, vastly increased their fat burn and athletic performance, even with minimal exercise. Some mice demonstrated the kind of endurance that would normally require intense training. Evans, a researcher at the Howard Hughes Medical Institute and the Salk Institute for Biological Studies, warned repeatedly that the pills weren't ready for human consumption when he published the study in 2008. They were just a proof of concept, he said, using some potentially dangerous substances. There were no studies showing they'd work on humans, no data on possible side effects.
Comment: Big pharma lobbyists creaming tens of billions out of the federal government in a variety of schemes